A small clinical trial conducted at London hospitals suggests dimethyltryptamine (DMT) may be an effective treatment for clinical depression. The study, involving 94 participants split between experimental and control groups, found that nearly half of those receiving a single DMT dose reported symptom improvements within a week, compared to just 6 percent in the placebo group.

DMT's appeal lies in its extremely short duration - with a half-life of only about five minutes, patients could be released from care shortly after treatment. This contrasts sharply with other psychedelics that can incapacitate users for hours. The trial combined the DMT dose with counseling, tracking depression symptoms weekly for 14 weeks post-treatment. While effects began to fade by the study's end, participants still showed significant improvement compared to baseline.

Researchers noted that antidepressant effects appeared linked to participants' mystical experiences during treatment, as measured by standardized questionnaires. The study found no serious side effects, with minor issues like injection site pain and brief increases in heart rate and blood pressure being short-lived. These findings suggest DMT's hallucinogenic properties may be inseparable from its therapeutic benefits, challenging the notion that psychedelic drugs could be modified to eliminate their mind-altering effects while retaining antidepressant properties.